Current and preclinical treatment options for Merkel cell carcinoma

References

• Harms KL, Healy MA, Nghiem P, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the New 8th edition AJCC staging system. Ann Surg Oncol. 2016 Oct;23(11):3564–3571. doi: 10.1245/s10434-016-5266-4
   PubMed Web of Science ®Google Scholar
• Stang A, Becker JC, Nghiem P, et al. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: an international assessment. Eur J Cancer. 2018 May;94:47–60.
   PubMed Web of Science ®Google Scholar
• Olsen CM, Pandeya N, Whiteman DC. International increases in Merkel cell carcinoma incidence rates between 1997 and 2016. J Invest Dermatol. 2021 Nov;141(11):2596–2601.e1. doi: 10.1016/j.jid.2021.04.007
   PubMed Web of Science ®Google Scholar
• Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018 Mar;78(3):457–463.e2. doi: 10.1016/j.jaad.2017.10.028
   PubMed Web of Science ®Google Scholar
• Jacobs D, Huang H, Olino K, et al. Assessment of age, period, and birth cohort effects and trends in Merkel cell carcinoma incidence in the United States. JAMA Dermatol. 2021 Jan 1;157(1):59–65. doi: 10.1001/jamadermatol.2020.4102
   PubMed Web of Science ®Google Scholar
• Eisemann N, Jansen L, Castro FA, et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol. 2016 Apr;174(4):778–785. doi: 10.1111/bjd.14352
   PubMed Web of Science ®Google Scholar
• Lewis CW, Qazi J, Hippe DS, et al. Patterns of distant metastases in 215 Merkel cell carcinoma patients: implications for prognosis and surveillance. Cancer Med. 2020 Feb;9(4):1374–1382. doi: 10.1002/cam4.2781
   PubMed Web of Science ®Google Scholar
• Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972 Jan;105(1):107–110. doi: 10.1001/archderm.1972.01620040075020
   PubMed Web of Science ®Google Scholar
• Kervarrec T. Evidence of an epithelial origin of Merkel cell carcinoma. Mod Pathol. 2022 Apr;35(4):446–448. doi: 10.1038/s41379-021-00964-x
   PubMed Web of Science ®Google Scholar
• Sunshine JC, Jahchan NS, Sage J, et al. Are there multiple cells of origin of Merkel cell carcinoma? Oncogene. 2018 Mar;37(11):1409–1416. doi: 10.1038/s41388-017-0073-3
   PubMed Web of Science ®Google Scholar
• Tilling T, Moll I. Which are the cells of origin in Merkel cell carcinoma? J Skin Cancer. 2012;2012:680410. doi: 10.1155/2012/680410
   PubMedGoogle Scholar
• Kervarrec T, Samimi M, Guyetant S, et al. Histogenesis of Merkel cell carcinoma: a comprehensive review. Front Oncol. 2019;9:451. doi: 10.3389/fonc.2019.00451
   PubMed Web of Science ®Google Scholar
• Nirenberg A, Steinman H, Dixon J, et al. Merkel cell carcinoma update: the case for two tumours. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1425–1431. doi: 10.1111/jdv.16158
   PubMed Web of Science ®Google Scholar
• Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Sci. 2008 Feb 22;319(5866):1096–1100. doi: 10.1126/science.1152586
   PubMed Web of Science ®Google Scholar
• Wijaya WA, Liu Y, Qing Y, et al. Prevalence of Merkel cell polyomavirus in normal and lesional skin: a systematic review and meta-analysis. Front Oncol. 2022;12:868781. doi: 10.3389/fonc.2022.868781
   PubMed Web of Science ®Google Scholar
• Paik JY, Hall G, Clarkson A, et al. Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population. Hum Pathol. 2011 Oct;42(10):1385–1390. doi: 10.1016/j.humpath.2010.12.013
   PubMed Web of Science ®Google Scholar
• Woodhouse B, Robb TJ, Hearn JI, et al. Merkel cell polyomavirus is uncommon in New Zealand Merkel cell carcinomas. Br J Dermatol. 2018 Nov;179(5):1197–1198. doi: 10.1111/bjd.16903
   PubMed Web of Science ®Google Scholar
• Harms PW, Vats P, Verhaegen ME, et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res. 2015 Sep 15;75(18):3720–3727. doi: 10.1158/0008-5472.CAN-15-0702
   PubMed Web of Science ®Google Scholar
• Goh G, Walradt T, Markarov V, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy [research support, N.I.H., extramural research support, non-U.S. Gov’t]. Oncotarget. 2016 Jan 19;7(3):3403–3415. doi: 10.18632/oncotarget.6494
   PubMedGoogle Scholar
• Starrett GJ, Marcelus C, Cantalupo PG, et al. Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated Merkel cell carcinoma. MBio. 2017 Jan 3;8(1). doi: 10.1128/mBio.02079-16
   PubMed Web of Science ®Google Scholar
• DeCaprio JA. Molecular pathogenesis of Merkel cell carcinoma. Annu Rev Pathol. 2021 Jan 24;16(1):69–91. doi: 10.1146/annurev-pathmechdis-012419-032817
   PubMedGoogle Scholar
• Shuda M, Feng H, Kwun HJ, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci, USA. 2008 Oct 21;105(42):16272–16277. doi: 10.1073/pnas.0806526105
   PubMed Web of Science ®Google Scholar
• Ahmed MM, Cushman CH, DeCaprio JA. Merkel cell polyomavirus: oncogenesis in a stable genome. Viruses. 2021 Dec 30;14(1):58. doi: 10.3390/v14010058
   PubMed Web of Science ®Google Scholar
• Hesbacher S, Pfitzer L, Wiedorfer K, et al. RB1 is the crucial target of the Merkel cell polyomavirus large T antigen in Merkel cell carcinoma cells. Oncotarget. 2016 May 31;7(22):32956–32968. doi: 10.18632/oncotarget.8793
   PubMedGoogle Scholar
• Houben R, Adam C, Baeurle A, et al. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer. 2012 Feb 15;130(4):847–856. doi: 10.1002/ijc.26076
   PubMed Web of Science ®Google Scholar
• Knepper TC, Montesion M, Russell JS, et al. The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy. Clin Cancer Res. 2019 Oct 1;25(19):5961–5971. doi: 10.1158/1078-0432.CCR-18-4159
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Synnott NC, O’Grady S, et al. Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2022 Feb;79:58–67.
   PubMed Web of Science ®Google Scholar
• Park DE, Cheng J, Berrios C, et al. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. Proc Natl Acad Sci, USA. 2019 Jan 15;116(3):1027–1032. doi: 10.1073/pnas.1818798116
   PubMed Web of Science ®Google Scholar
• Mistry K, Levell NJ, Craig P, et al. Merkel cell carcinoma. Skin Health Dis. 2021 Dec;1(4):e55. doi: 10.1002/ski2.55
   PubMedGoogle Scholar
• Moshiri AS, Doumani R, Yelistratova L, et al. Polyomavirus-Negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. J Invest Dermatol. 2017 Apr;137(4):819–827. doi: 10.1016/j.jid.2016.10.028
   PubMed Web of Science ®Google Scholar
• Bichakjian CK, Olencki T, Aasi SZ, et al. Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018 Jun;16(6):742–774. doi: 10.6004/jnccn.2018.0055
   PubMed Web of Science ®Google Scholar
• Gauci ML, Aristei C, Becker JC, et al. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – update 2022. Eur J Cancer. 2022 Aug;171:203–231.
   PubMed Web of Science ®Google Scholar
• Tam M, Luu M, Barker CA, et al. Improved survival in women versus men with Merkel cell carcinoma. J Am Acad Dermatol. 2021 Feb;84(2):321–329. doi: 10.1016/j.jaad.2020.02.034
   PubMed Web of Science ®Google Scholar
• Farley CR, Perez MC, Soelling SJ, et al. Merkel cell carcinoma outcomes: does AJCC8 underestimate survival? Ann Surg Oncol. 2020 Jun;27(6):1978–1985. doi: 10.1245/s10434-019-08187-w
   PubMed Web of Science ®Google Scholar
• Esposito A, Jacobs D, Ariyan S, et al. Merkel cell carcinoma: changing practice patterns and impact on recurrence-free and overall survival at a single institution and nationally. Ann Surg Oncol. 2022 Jan;29(1):415–424. doi: 10.1245/s10434-021-10727-2
   PubMedGoogle Scholar
• Yang A, Wijaya WA, Yang L, et al. The impact of Merkel cell polyomavirus positivity on prognosis of Merkel cell carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:1020805. doi: 10.3389/fonc.2022.1020805
   PubMed Web of Science ®Google Scholar
• Kervarrec T, Tallet A, Miquelestorena-Standley E, et al. Morphologic and immunophenotypical features distinguishing Merkel cell polyomavirus-positive and negative Merkel cell carcinoma. Mod Pathol. 2019 Nov;32(11):1605–1616. doi: 10.1038/s41379-019-0288-7
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Matsushita M, Kuwamoto S, et al. Usefulness of significant morphologic characteristics in distinguishing between Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative Merkel cell carcinomas. Hum Pathol. 2013 Sep;44(9):1912–1917. doi: 10.1016/j.humpath.2013.01.026
   PubMed Web of Science ®Google Scholar
• Kitamura N, Tomita R, Yamamoto M, et al. Complete remission of Merkel cell carcinoma on the upper lip treated with radiation monotherapy and a literature review of Japanese cases. World J Surg Oncol. 2015 Apr 17;13(1):152. doi: 10.1186/s12957-015-0564-z
   PubMedGoogle Scholar
• Fenig E, Brenner B, Katz A, et al. The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer. 1997 Sep 1;80(5):881–885. doi: 10.1002/(SICI)1097-0142(19970901)80:5<881:AID-CNCR8>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Harrington C, Kwan W. Outcomes of Merkel cell carcinoma treated with radiotherapy without radical surgical excision. Ann Surg Oncol. 2014 Oct;21(11):3401–3405. doi: 10.1245/s10434-014-3757-8
   PubMed Web of Science ®Google Scholar
• Cassler NM, Merrill D, Bichakjian CK, et al. Merkel cell carcinoma therapeutic update. Curr Treat Options Oncol. 2016 Jul;17(7):36. doi: 10.1007/s11864-016-0409-1
   PubMed Web of Science ®Google Scholar
• Nghiem P, Kaufman HL, Bharmal M, et al. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017 Jun;13(14):1263–1279. doi: 10.2217/fon-2017-0072
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374–1385. doi: 10.1016/S1470-2045(16)30364-3
   PubMed Web of Science ®Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma [clinical trial, phase II multicenter study research support, N.I.H., extramural research support, non-U.S. Gov’t]. N Engl J Med. 2016 Jun 30;374(26):2542–2552. doi: 10.1056/NEJMoa1603702
   PubMedGoogle Scholar
• Nghiem P, Bhatia S, Lipson EJ, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immuno therapy cancer. 2021 Apr;9(4):e002478. doi: 10.1136/jitc-2021-002478
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021 Dec;6(6):100290. doi: 10.1016/j.esmoop.2021.100290
   PubMed Web of Science ®Google Scholar
• Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015 Apr;33:23–35. doi: 10.1016/j.coi.2015.01.006
   PubMed Web of Science ®Google Scholar
• Bhatia S, Nghiem P, Veeranki SP, et al. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immuno therapy cancer. 2022 Aug;10(8):e004904. doi: 10.1136/jitc-2022-004904
   PubMed Web of Science ®Google Scholar
• Topalian SL, Bhatia S, Hollebecque A, et al. Abstract CT074: non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res. 2017;77(13_Supplement):CT074–CT074. doi: 10.1158/1538-7445.AM2017-CT074
   Google Scholar
• Grignani G, Rutkowski P, Lebbe C, et al. 545 545 A phase 2 study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) (POD1UM-201). J ImmunoTherapy Cancer. 2021;9(Suppl 2):A574–A575. doi: 10.1136/jitc-2021-SITC2021.545
   Google Scholar
• Bradford D, Demko S, Jin S, et al. FDA accelerated approval of pembrolizumab for recurrent locally advanced or metastatic Merkel cell carcinoma. Oncol. 2020 Jul;25(7):e1077–e1082. doi: 10.1634/theoncologist.2020-0184
   Google Scholar
• Amiot M, Brunet Possenti F, Lebbé C, et al. Successful rechallenge with avelumab in Merkel cell carcinoma. Eur J Cancer. 2021 Aug;153:96–97.
   PubMed Web of Science ®Google Scholar
• Stege HM, Bradfisch F, Fleischer MI, et al. Retrospective multicenter analysis of the outcome of a re-induction with immune checkpoint inhibitors in advanced Merkel cell carcinoma. SN Compr Clin Med. 2020 Nov 01;2(11):2202–2207. doi: 10.1007/s42399-020-00488-6
   Google Scholar
• Weppler AM, Da Meda L, Pires da Silva I, et al. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. Eur J Cancer. 2023 Apr;183:109–118.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J ImmunoTherapy Cancer. 2020 May;8(1):e000674. doi: 10.1136/jitc-2020-000674
   PubMed Web of Science ®Google Scholar
• Xu MJ, Wu S, Daud AI, et al. In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. J ImmunoTherapy Cancer. 2018 May 30;6(1):43. doi: 10.1186/s40425-018-0352-8
   PubMedGoogle Scholar
• Bloom BC, Augustyn A, Pezzi TA, et al. Rescue of immunotherapy-refractory metastatic Merkel cell carcinoma with conventionally fractionated radiotherapy and concurrent pembrolizumab. Front Oncol. 2019;9:223. doi: 10.3389/fonc.2019.00223
   PubMed Web of Science ®Google Scholar
• Schaub SK, Stewart RD, Sandison GA, et al. Does neutron radiation therapy potentiate an immune response to Merkel cell carcinoma? Int J Part Ther. 2018 Summer;5(1):183–195. doi: 10.14338/IJPT-18-00012.1
   PubMedGoogle Scholar
• Kim S, Wuthrick E, Blakaj D, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep 24;400(10357):1008–1019. doi: 10.1016/S0140-6736(22)01659-2
   PubMed Web of Science ®Google Scholar
• Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in Cancer therapy. Curr Oncol. 2022 Apr 24;29(5):3044–3060. doi: 10.3390/curroncol29050247
   PubMed Web of Science ®Google Scholar
• LoPiccolo J, Schollenberger MD, Dakhil S, et al. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. J ImmunoTherapy Cancer. 2019 Jul 8;7(1):170. doi: 10.1186/s40425-019-0661-6
   PubMedGoogle Scholar
• Shalhout SZ, Emerick KS, Kaufman HL, et al. A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory Merkel cell carcinoma. J Immunother. 2022 Sep 1;45(7):299–302. doi: 10.1097/CJI.0000000000000432
   PubMed Web of Science ®Google Scholar
• Glutsch V, Schummer P, Kneitz H, et al. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. J ImmunoTherapy Cancer. 2022 Nov;10(11):e005930. doi: 10.1136/jitc-2022-005930
   PubMed Web of Science ®Google Scholar
• Zhou S, Khanal S, Zhang H. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag. 2019;15: 211–221. doi: 10.2147/TCRM.S193338
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31–41. doi: 10.1016/S1470-2045(16)30624-6
   PubMed Web of Science ®Google Scholar
• Paulson KG, Tegeder A, Willmes C, et al. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res. 2014 Nov;2(11):1071–1079. doi: 10.1158/2326-6066.CIR-14-0005
   PubMed Web of Science ®Google Scholar
• Lee PC, Klaeger S, Le PM, et al. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J Clin Invest. 2022 Jul 1;132(13). doi: 10.1172/JCI151666
   Web of Science ®Google Scholar
• Ritter C, Fan K, Paschen A, et al. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017 May 23;7(1):2290. doi: 10.1038/s41598-017-02608-0
   PubMedGoogle Scholar
• Paulson KG, Iyer JG, Simonson WT, et al. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am J Clin Pathol. 2014 Oct;142(4):452–458. doi: 10.1309/AJCPIKDZM39CRPNC
   PubMed Web of Science ®Google Scholar
• Sihto H, Joensuu H. Tumor-infiltrating lymphocytes and outcome in Merkel cell carcinoma, a virus-associated cancer. Oncoimmunol. 2012 Nov 1;1(8):1420–1421. doi: 10.4161/onci.21120
   PubMed Web of Science ®Google Scholar
• Miller NJ, Church CD, Dong L, et al. Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival. Cancer Immunol Res. 2017 Feb;5(2):137–147. doi: 10.1158/2326-6066.CIR-16-0210
   PubMed Web of Science ®Google Scholar
• Hansen UK, Lyngaa R, Ibrani D, et al. Extended T-Cell epitope landscape in Merkel cell polyomavirus large T and small T oncoproteins identified uniquely in patients with Cancer. J Invest Dermatol. 2022 Jan;142(1):239–243 e13. doi: 10.1016/j.jid.2021.06.027
   PubMed Web of Science ®Google Scholar
• Joshi TP, Farr MA, Hsiou DA, et al. Therapeutic targets for vaccination in polyomavirus-driven Merkel cell carcinoma. Dermatol Ther. 2022 Jul;35(7):e15580. doi: 10.1111/dth.15580
   PubMed Web of Science ®Google Scholar
• Tabachnick-Cherny S, Pulliam T, Church C, et al. Polyomavirus-driven Merkel cell carcinoma: prospects for therapeutic vaccine development. Mol Carcinog. 2020 Jul;59(7):807–821. doi: 10.1002/mc.23190
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69–74. doi: 10.1126/science.aaa4971
   PubMed Web of Science ®Google Scholar
• Shuda M, Kwun HJ, Feng H, et al. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest. 2011 Sep;121(9):3623–3634. doi: 10.1172/JCI46323
   PubMed Web of Science ®Google Scholar
• Houben R, Shuda M, Weinkam R, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol. 2010 Jul;84(14):7064–7072. doi: 10.1128/JVI.02400-09
   PubMed Web of Science ®Google Scholar
• Iyer JG, Afanasiev OK, McClurkan C, et al. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res. 2011 Nov 1;17(21):6671–6680. doi: 10.1158/1078-0432.CCR-11-1513
   PubMed Web of Science ®Google Scholar
• Lyngaa R, Pedersen NW, Schrama D, et al. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors [research support, non-U.S. Gov’t]. Clin Cancer Res. 2014 Apr 1;20(7):1768–1778. doi: 10.1158/1078-0432.CCR-13-2697
   PubMed Web of Science ®Google Scholar
• Samimi M, Benlalam H, Aumond P, et al. Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma. Cell Immunol. 2019 Oct;344:103961.
   PubMed Web of Science ®Google Scholar
• Jing L, Ott M, Church CD, et al. Prevalent and diverse intratumoral oncoprotein-specific CD8+ T cells within polyomavirus-driven Merkel cell carcinomas. Cancer Immunol Res. 2020 May;8(5):648–659. doi: 10.1158/2326-6066.CIR-19-0647
   PubMed Web of Science ®Google Scholar
• Church C, Pulliam T, Longino N, et al. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. J ImmunoTherapy Cancer. 2022 Sep;10(9):e005328. doi: 10.1136/jitc-2022-005328
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJP, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009 Nov 5;361(19):1838–1847. doi: 10.1056/NEJMoa0810097
   PubMed Web of Science ®Google Scholar
• Gomez B, He L, Tsai YC, et al. Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen. Cell Biosci. 2013;3(1):29. doi: 10.1186/2045-3701-3-29
   PubMedGoogle Scholar
• Gomez BP, Wang C, Viscidi RP, et al. Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of Merkel cell polyomavirus large T antigen. Cell Biosci. 2012 Oct 24;2(1):36. doi: 10.1186/2045-3701-2-36
   PubMedGoogle Scholar
• Gerer KF, Erdmann M, Hadrup SR, et al. Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. Therapeut Adv Med Oncol. 2017 Jul;9(7):451–464. doi: 10.1177/1758834017712630
   PubMed Web of Science ®Google Scholar
• Xu D, Jiang S, He Y, et al. Development of a therapeutic vaccine targeting Merkel cell polyomavirus capsid protein VP1 against Merkel cell carcinoma. NPJ Vaccines. 2021 Oct 5;6(1):119. doi: 10.1038/s41541-021-00382-9
   PubMed Web of Science ®Google Scholar
• Touze A, Le Bidre E, Laude H, et al. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J Clin Oncol. 2011 Apr 20;29(12):1612–1619. doi: 10.1200/JCO.2010.31.1704
   PubMed Web of Science ®Google Scholar
• Schrama D, Hesbacher S, Angermeyer S, et al. Serine 220 phosphorylation of the Merkel cell polyomavirus large T antigen crucially supports growth of Merkel cell carcinoma cells. Int J Cancer. 2016 Mar 1;138(5):1153–1162. doi: 10.1002/ijc.29862
   PubMed Web of Science ®Google Scholar
• Ruff AL, Guarnieri FG, Staveley-O’Carroll K, et al. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem. 1997 Mar 28;272(13):8671–8678. doi: 10.1074/jbc.272.13.8671
   PubMed Web of Science ®Google Scholar
• Teixeira FME, Oliveira LM, Pietrobon AJ, et al. LAMP-1 chimeric to HIV-1 p55Gag in the immunization of neonate mice induces an early germinal center formation and AID expression. Vaccines (Basel). 2022 Aug 3;10(8):1246. doi: 10.3390/vaccines10081246
   PubMed Web of Science ®Google Scholar
• Brohl AS, Markowitz J, Eroglu Z, et al. Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma. J Clin Oncol. 2023;41(16_suppl):9534–9534. doi: 10.1200/JCO.2023.41.16_suppl.9534
   Google Scholar
• Ferrucci PF, Pala L, Conforti F, et al. Talimogene Laherparepvec (T-VEC): an intralesional Cancer immunotherapy for advanced melanoma. Cancers. 2021 Mar 18;13(6):1383. doi: 10.3390/cancers13061383
   PubMed Web of Science ®Google Scholar
• Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5(1):e1115641. doi: 10.1080/2162402X.2015.1115641
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003 Feb;10(4):292–303. doi: 10.1038/sj.gt.3301885
   PubMed Web of Science ®Google Scholar
• Casale F, Tchanque-Fossuo C, Stepenaskie S, et al. Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy. Dermatol Online J. 2022 Jan 15;28(1). doi: 10.5070/D328157059
   Google Scholar
• Cilento MA, Klein O, Egan E, et al. Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma. Australas J Dermatol. 2022 Aug;63(3):e222–e225. doi: 10.1111/ajd.13881
   PubMed Web of Science ®Google Scholar
• Westbrook BC, Norwood TG, Terry NLJ, et al. Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients. JAAD Case Rep. 2019 Sep;5(9):782–786. doi: 10.1016/j.jdcr.2019.06.034
   PubMedGoogle Scholar
• Lara KM, In GK, Matcuk GR Jr., et al. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov;4(10):1004–1006. doi: 10.1016/j.jdcr.2018.10.003
   PubMedGoogle Scholar
• Nguyen MHK, Leong SP, Abendroth R, et al. Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma. JAAD Case Rep. 2019 Oct;5(10):849–851. doi: 10.1016/j.jdcr.2019.07.006
   PubMedGoogle Scholar
• Hirotsu KE, Hua V, Tran AT, et al. Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient. JAAD Case Rep. 2021 Jul;13:144–146.
   PubMedGoogle Scholar
• Chapuis AG, Afanasiev OK, Iyer JG, et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I [case reports]. Cancer Immunol Res. 2014 Jan;2(1):27–36. doi: 10.1158/2326-6066.CIR-13-0087
   PubMed Web of Science ®Google Scholar
• Paulson KG, Perdicchio M, Kulikauskas R, et al. Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab. J Clin Oncol. 2017;35(15_suppl):3044–3044. doi: 10.1200/JCO.2017.35.15_suppl.3044
   Google Scholar
• Davies SI, Barrett J, Wong S, et al. Robust production of Merkel cell polyomavirus oncogene specific T cells from healthy donors for adoptive transfer. Front Immunol. 2020;11:592721. doi: 10.3389/fimmu.2020.592721
   PubMed Web of Science ®Google Scholar
• Veatch J, Akkiraju A, Darwanto A, et al. ATTAC-MCC: phase I/II study of autologous CD8+ and CD4+ transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade. J Clin Oncol. 2022;40(16_suppl):TPS9596–TPS9596. doi: 10.1200/JCO.2022.40.16_suppl.TPS9596
   Web of Science ®Google Scholar
• Muralidharan S, Kervarrec T, Weiss GJ, et al. Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma. Oncotarget. 2022;13(1):960–967. doi: 10.18632/oncotarget.28260
   PubMedGoogle Scholar
• Iyoda T, Yamasaki S, Ueda S, et al. Natural killer T and Natural killer cell-based immunotherapy strategies targeting Cancer. Biomolecules. 2023 Feb 10;13(2):348. doi: 10.3390/biom13020348
   PubMed Web of Science ®Google Scholar
• Bhatia SC, Paulson C, Pierce K, et al. Society for Immunotherapy of Cancer; 2019. SITC 2019.
   Google Scholar
• Fabian KP, Padget MR, Donahue RN, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immuno therapy cancer. 2020 May;8(1):e000450. doi: 10.1136/jitc-2019-000450
   PubMed Web of Science ®Google Scholar
• Davalos V, Esteller M. Cancer epigenetics in clinical practice. Ca A Cancer J Clinicians. 2022 Dec 13;73(4):376–424. doi: 10.3322/caac.21765
   PubMed Web of Science ®Google Scholar
• Kervarrec T, Aljundi M, Appenzeller S, et al. Polyomavirus-positive Merkel cell carcinoma derived from a trichoblastoma suggests an epithelial origin of this Merkel cell carcinoma. J Invest Dermatol. 2020 May;140(5):976–985. doi: 10.1016/j.jid.2019.09.026
   PubMed Web of Science ®Google Scholar
• Kervarrec T, Appenzeller S, Samimi M, et al. Merkel cell polyomavirus‒Negative Merkel cell carcinoma originating from in situ squamous cell carcinoma: a keratinocytic tumor with neuroendocrine differentiation. J Invest Dermatol. 2022 Mar;142(3):516–527. doi: 10.1016/j.jid.2021.07.175
   PubMed Web of Science ®Google Scholar
• Harms PW, Verhaegen ME, Hu K, et al. Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors. Mod Pathol. 2022 Apr;35(4):506–514. doi: 10.1038/s41379-021-00928-1
   PubMed Web of Science ®Google Scholar
• DeCoste RC, Walsh NM, Gaston D, et al. RB1-deficient squamous cell carcinoma: the proposed source of combined Merkel cell carcinoma. Mod Pathol. 2022 Sep 8;35(12):1829–1836. doi: 10.1038/s41379-022-01151-2
   PubMed Web of Science ®Google Scholar
• Park DE, Cheng J, McGrath JP, et al. Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. Nat Cell Biol. 2020 May;22(5):603–615. doi: 10.1038/s41556-020-0503-2
   PubMed Web of Science ®Google Scholar
• Leiendecker L, Jung PS, Krecioch I, et al. LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma. EMBO Mol Med. 2020 Nov 6;12(11):e12525. doi: 10.15252/emmm.202012525
   PubMed Web of Science ®Google Scholar
• Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010 Jan;31(1):27–36. doi: 10.1093/carcin/bgp220
   PubMed Web of Science ®Google Scholar
• Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004 Dec 29;119(7):941–953. doi: 10.1016/j.cell.2004.12.012
   PubMed Web of Science ®Google Scholar
• Inui K, Zhao Z, Yuan J, et al. Stepwise assembly of functional C-terminal REST/NRSF transcriptional repressor complexes as a drug target. Protein Sci. 2017 May;26(5):997–1011. doi: 10.1002/pro.3142
   PubMed Web of Science ®Google Scholar
• Wobser M, Weber A, Glunz A, et al. Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells. J Hematol Oncol. 2019 Mar 18;12(1):30. doi: 10.1186/s13045-019-0719-4
   PubMedGoogle Scholar
• Song L, Bretz AC, Gravemeyer J, et al. The HDAC inhibitor domatinostat promotes cell-cycle arrest, induces apoptosis, and increases immunogenicity of Merkel cell carcinoma cells. J Invest Dermatol. 2021 Apr;141(4):903–912 e4. doi: 10.1016/j.jid.2020.08.023
   PubMed Web of Science ®Google Scholar
• Zeng J, Zhang J, Sun Y, et al. Targeting EZH2 for cancer therapy: from current progress to novel strategies. Eur J Med Chem. 2022 Aug 5;238:114419. doi: 10.1016/j.ejmech.2022.114419
   PubMed Web of Science ®Google Scholar
• An R, Li YQ, Lin YL, et al. EZH1/2 as targets for cancer therapy. Cancer Gene Ther. 2022 Nov 11;30(2):221–235. doi: 10.1038/s41417-022-00555-1
   PubMed Web of Science ®Google Scholar
• Barghout SH, Machado RAC, Barsyte-Lovejoy D. Chemical biology and pharmacology of histone lysine methylation inhibitors. Biochim Biophys Acta, Gene Regul Mech. 2022 Aug;1865(6):194840. doi: 10.1016/j.bbagrm.2022.194840
   PubMed Web of Science ®Google Scholar
• Dou F, Tian Z, Yang X, et al. Valemetostat: first approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. DD&T. 2022 Oct 28;16(6):297–299. doi: 10.5582/ddt.2022.01085
   Google Scholar
• Bardot ES, Valdes VJ, Zhang J, et al. Polycomb subunits Ezh1 and Ezh2 regulate the Merkel cell differentiation program in skin stem cells [research support, N.I.H., extramural research support, non-U.S. Gov’t research support, U.S. Gov’t, non-P.H.S.]. EMBO J. 2013 Jul 17;32(14):1990–2000. doi: 10.1038/emboj.2013.110
   PubMed Web of Science ®Google Scholar
• Perdigoto CN, Dauber KL, Bar C, et al. Polycomb-mediated repression and sonic hedgehog signaling interact to regulate Merkel cell specification during skin development. PLoS Genet. 2016 Jul;12(7):e1006151. doi: 10.1371/journal.pgen.1006151
   PubMed Web of Science ®Google Scholar
• Harms KL, Chubb H, Zhao L, et al. Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis. Hum Pathol. 2017 Sep;67:78–84.
   PubMed Web of Science ®Google Scholar
• Veija T, Koljonen V, Bohling T, et al. Aberrant expression of ALK and EZH2 in Merkel cell carcinoma. BMC Cancer. 2017 Mar 31;17(1):236. doi: 10.1186/s12885-017-3233-5
   PubMedGoogle Scholar
• Matsushita M, Iwasaki T, Wardhani LO, et al. Decreased H3K27me3 expression is associated with Merkel cell polyomavirus-negative Merkel cell carcinoma, especially combined with cutaneous squamous cell carcinoma. Anticancer Res. 2019 Oct;39(10):5573–5579. doi: 10.21873/anticanres.13751
   PubMed Web of Science ®Google Scholar
• Busam KJ, Pulitzer MP, Coit DC, et al. Reduced H3K27me3 expression in Merkel cell polyoma virus-positive tumors. Mod Pathol. 2017 Jun;30(6):877–883. doi: 10.1038/modpathol.2017.8
   PubMed Web of Science ®Google Scholar
• Durand MA, Drouin A, Mouchard A, et al. Distinct Regulation of EZH2 and its repressive H3K27me3 Mark in polyomavirus-positive and -negative Merkel cell carcinoma. J Invest Dermatol. 2023 Apr 8. doi: 10.1016/j.jid.2023.02.038
   Google Scholar
• Gartin AK, Frost TC, Cushman CH, et al. Merkel cell carcinoma sensitivity to EZH2 inhibition is mediated by SIX1 derepression. J Invest Dermatol. 2022 Oct;142(10):2783–2792 e15. doi: 10.1016/j.jid.2022.03.008
   PubMed Web of Science ®Google Scholar
• Khattri M, Amako Y, Gibbs JR, et al. Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirus. Tumour Virus Res. 2023 Jun 2;16:200264. doi: 10.1016/j.tvr.2023.200264
   PubMedGoogle Scholar
• Harms PW, Verhaegen ME, Vo JN, et al. Viral status predicts the patterns of genome methylation and decitabine response in Merkel cell carcinoma. J Invest Dermatol. 2022 Mar;142(3 Pt A):641–652. doi: 10.1016/j.jid.2021.07.173
   PubMed Web of Science ®Google Scholar
• Xu K, Hansen E. Novel agents for myelodysplastic syndromes. J Oncol Pharm Pract. 2021 Dec;27(8):1982–1992. doi: 10.1177/10781552211037993
   PubMed Web of Science ®Google Scholar
• Ananthapadmanabhan V, Frost TC, Soroko KM, et al. Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. JCI Insight. 2022 Jul 8;7(13). doi: 10.1172/jci.insight.160513
   PubMedGoogle Scholar
• Houben R, Dreher C, Angermeyer S, et al. Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens. J Invest Dermatol. 2013 Oct;133(10):2453–2460. doi: 10.1038/jid.2013.169
   PubMed Web of Science ®Google Scholar
• Wong MKK, Burgess MA, Chandra S, et al. Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC). J Clin Oncol. 2022;40(16_suppl):9506–9506. doi: 10.1200/JCO.2022.40.16_suppl.9506
   Google Scholar
• Gardair C, Samimi M, Touze A, et al. Somatostatin receptors 2A and 5 are expressed in Merkel cell carcinoma with no association with disease severity. Neuroendocrinology. 2015;101(3):223–235. doi: 10.1159/000381062
   PubMed Web of Science ®Google Scholar
• Akaike T, Qazi J, Anderson A, et al. High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma. Br J Dermatol. 2021 Feb;184(2):319–327. doi: 10.1111/bjd.19150
   PubMed Web of Science ®Google Scholar
• Leccia MT, Mouret S, Dalle S, et al. Traitement des carcinomes de Merkel inopérables et/ou métastatiques par analogue de la somatostatine. Étude nationale multicentrique mono-bras de phase II. Annales de Dermatologie et de Vénéréologie. 2018 Dec 01;145(12):S126. doi: 10.1016/j.annder.2018.09.142
   Google Scholar
• Dash A, Chakraborty S, Pillai MR, et al. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 2015 Mar;30(2):47–71. doi: 10.1089/cbr.2014.1741
   PubMed Web of Science ®Google Scholar
• Hofland J, Brabander T, Verburg FA, et al. Peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2022 Oct 5;107(12):3199–3208. doi: 10.1210/clinem/dgac574
   PubMed Web of Science ®Google Scholar
• Askari E, Moghadam SZ, Wild D, et al. Peptide receptor radionuclide therapy in Merkel cell carcinoma: a comprehensive review. J Nucl Med Technol. 2022 Oct 4;51(1):22–25. doi: 10.2967/jnmt.122.264904
   PubMed Web of Science ®Google Scholar
• Pander G, Uhl P, Kuhl N, et al. Antibody–drug conjugates: what drives their progress? Drug Discov Today. 2022 Oct;27(10):103311. doi: 10.1016/j.drudis.2022.06.011
   PubMed Web of Science ®Google Scholar
• Ollier J, Kervarrec T, Samimi M, et al. Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 2018 Aug;67(8):1209–1219. doi: 10.1007/s00262-018-2176-2
   PubMed Web of Science ®Google Scholar
• Shah MH, Lorigan P, O’Brien ME, et al. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs. 2016 Jun;34(3):290–299. doi: 10.1007/s10637-016-0336-9
   PubMed Web of Science ®Google Scholar
• Socinski MA, Kaye FJ, Spigel DR, et al. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung Cancer patients with Extensive-stage disease. Clin Lung Cancer. 2017 Jan;18(1):68–76 e2. doi: 10.1016/j.cllc.2016.09.002
   PubMed Web of Science ®Google Scholar
• Esnault C, Leblond V, Martin C, et al. Adcitmer((r)), a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. Br J Dermatol. 2022 Feb;186(2):295–306. doi: 10.1111/bjd.20770
   PubMed Web of Science ®Google Scholar
• Kervarrec T, Gaboriaud P, Tallet A, et al. VEGF-A inhibition as a potential therapeutic approach in Merkel cell carcinoma. J Invest Dermatol. 2019 Mar;139(3):736–739. doi: 10.1016/j.jid.2018.08.029
   PubMed Web of Science ®Google Scholar
• Knepper TC, Panchaud RA, Muradova E, et al. An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response. Cancer Med. 2021 Sep;10(17):5889–5896. doi: 10.1002/cam4.4138
   PubMed Web of Science ®Google Scholar
• Tarabadkar ES, Thomas H, Blom A, et al. Clinical benefit from tyrosine kinase inhibitors in metastatic Merkel cell carcinoma: a case series of 5 patients. Am J Case Rep. 2018 Apr 30;19:505–511. doi: 10.12659/AJCR.908649
   PubMed Web of Science ®Google Scholar
• Samlowski WE, Moon J, Tuthill RJ, et al. A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest oncology group study (S0331). Am J Clin Oncol. 2010 Oct;33(5):495–499. doi: 10.1097/COC.0b013e3181b9cf04
   PubMed Web of Science ®Google Scholar
• Rabinowits G, Lezcano C, Catalano PJ, et al. Cabozantinib in patients with advanced Merkel cell carcinoma. Oncology. 2018 Jul;23(7):814–821. doi: 10.1634/theoncologist.2017-0552
   Google Scholar
• Nathan PD, Gaunt P, Wheatley K, et al. UKMCC-01: a phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma. J Clin Oncol. 2016;34(15_suppl):9542–9542. doi: 10.1200/JCO.2016.34.15_suppl.9542
   Web of Science ®Google Scholar
• Cheng J, Park DE, Berrios C, et al. Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLOS Pathog. 2017 Oct;13(10):e1006668. doi: 10.1371/journal.ppat.1006668
   PubMed Web of Science ®Google Scholar
• Verhaegen ME, Mangelberger D, Harms PW, et al. Merkel cell polyomavirus small T antigen Initiates Merkel cell carcinoma-like tumor development in mice. Cancer Res. 2017 Jun 15;77(12):3151–3157. doi: 10.1158/0008-5472.CAN-17-0035
   PubMed Web of Science ®Google Scholar
• Kwun HJ, Shuda M, Feng H, et al. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe. 2013 Aug 14;14(2):125–135. doi: 10.1016/j.chom.2013.06.008
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844–848. doi: 10.1126/science.1092472
   PubMed Web of Science ®Google Scholar
• Yap JL, Wang H, Hu A, et al. Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorganic Med Chem Lett. 2013 Jan 1;23(1):370–374. doi: 10.1016/j.bmcl.2012.10.013
   PubMed Web of Science ®Google Scholar
• Lu H, Zhou Q, He J, et al. Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5(1):213. doi: 10.1038/s41392-020-00315-3
   PubMed Web of Science ®Google Scholar
• Houben R, Hesbacher S, Sarma B, et al. Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs Merkel cell carcinoma cell growth. Cancer Lett. 2022 Jan 1;524:259–267. doi: 10.1016/j.canlet.2021.10.031
   PubMed Web of Science ®Google Scholar
• Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014 Sep;46(6):372–383. doi: 10.3109/07853890.2014.912836
   PubMed Web of Science ®Google Scholar
• Hafner C, Houben R, Baeurle A, et al. Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One. 2012;7(2):e31255. doi: 10.1371/journal.pone.0031255
   PubMed Web of Science ®Google Scholar
• Nardi V, Song Y, Santamaria-Barria JA, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 1;18(5):1227–1236. doi: 10.1158/1078-0432.CCR-11-2308
   PubMed Web of Science ®Google Scholar
• Lin Z, McDermott A, Shao L, et al. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. Cancer Lett. 2014 Mar 28;344(2):272–281. doi: 10.1016/j.canlet.2013.11.005
   PubMed Web of Science ®Google Scholar
• Kannan A, Lin Z, Shao Q, et al. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth. Oncotarget. 2016 Feb 9;7(6):6576–6592. doi: 10.18632/oncotarget.5878
   PubMedGoogle Scholar
• Ali ES, Mitra K, Akter S, et al. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int. 2022 Sep 15;22(1):284. doi: 10.1186/s12935-022-02706-8
   PubMed Web of Science ®Google Scholar
• Sundqvist B, Kilpinen S, Böhling T, et al. Activation of oncogenic and immune-response pathways is linked to disease-specific survival in Merkel cell carcinoma. Cancers. 2022 Jul 23;14(15):3591. doi: 10.3390/cancers14153591
   PubMed Web of Science ®Google Scholar
• Shiver MB, Mahmoud F, Gao L. Response to Idelalisib in a patient with stage IV Merkel-cell carcinoma. N Engl J Med. 2015 Oct 15;373(16):1580–1582. doi: 10.1056/NEJMc1507446
   PubMed Web of Science ®Google Scholar
• Fang B, Kannan A, Zhao S, et al. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. Sci Rep. 2020 Jun 1;10(1):8867. doi: 10.1038/s41598-020-65637-2
   PubMed Web of Science ®Google Scholar
• Chteinberg E, Wetzels S, Gerritsen W, et al. Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro. Therapeut Adv Med Oncol. 2020;12:1758835920975621. doi: 10.1177/1758835920975621
   Web of Science ®Google Scholar
• Wu JH, Limmer AL, Narayanan D, et al. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth. Clin Exp Dermatol. 2021 Dec;46(8):1551–1554. doi: 10.1111/ced.14798
   PubMed Web of Science ®Google Scholar
• Koubek EJ, Weissenrieder JS, Ortiz LE, et al. Therapeutic potential of 5′-methylschweinfurthin G in Merkel cell polyomavirus-positive Merkel cell carcinoma. Viruses. 2022 Aug 23;14(9):1848. doi: 10.3390/v14091848
   PubMed Web of Science ®Google Scholar
• Efferth T. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 2017 Oct;46:65–83. doi: 10.1016/j.semcancer.2017.02.009
   PubMed Web of Science ®Google Scholar
• Heller LE, Roepe PD. Artemisinin-based antimalarial drug therapy: molecular pharmacology and evolving resistance. Tropical medicine and infectious disease. Trop Med Infect Dis. 2019 Jun 4;4(2):89. doi: 10.3390/tropicalmed4020089
   PubMedGoogle Scholar
• Burrows JN, Chibale K, Wells TN. The state of the art in anti-malarial drug discovery and development. Curr Top Med Chem. 2011;11(10):1226–1254. doi: 10.2174/156802611795429194
   PubMed Web of Science ®Google Scholar
• Sarma B, Willmes C, Angerer L, et al. Artesunate Affects T antigen expression and survival of virus-positive Merkel cell carcinoma. Cancers. 2020 Apr 9;12(4):919. doi: 10.3390/cancers12040919
   PubMed Web of Science ®Google Scholar
• Kufe DW. MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis. 2020 Sep 24;41(9):1173–1183. doi: 10.1093/carcin/bgaa082
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Fushimi A, Yamashita N, et al. Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. Oncogene. 2022 Jul;41(27):3511–3523. doi: 10.1038/s41388-022-02361-3
   PubMed Web of Science ®Google Scholar
• Walker JW, Lebbe C, Grignani G, et al. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immuno therapy cancer. 2020 Apr;8(1):e000313. doi: 10.1136/jitc-2019-000313
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Orlova K, Grignani G, et al. Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East. Int J Cancer. 2021 Dec 1;149(11):1926–1934. doi: 10.1002/ijc.33746
   PubMed Web of Science ®Google Scholar
• Banna GL, Cantale O, Bersanelli M, et al. Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. Oncol Rev. 2020 Jul 6;14(2):490. doi: 10.4081/oncol.2020.490
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Lebbé C, Mortier L, et al. 604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial. J Immuno therapy cancer. 2022;10(Suppl 2):A633–A633.
   Google Scholar
• Fabian KP, Wolfson B, Hodge JW. From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment. Front Oncol. 2021;11:728018. doi: 10.3389/fonc.2021.728018
   PubMed Web of Science ®Google Scholar
• Spassova I, Ugurel S, Kubat L, et al. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. J Immuno therapy cancer. 2022 Jan;10(1):e003198. doi: 10.1136/jitc-2021-003198
   PubMed Web of Science ®Google Scholar
• Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO guidelines Committee. Ann Of Oncol Off J Eur Soc Med Oncol/ESMO. 2020 Nov;31(11):1435–1448. doi: 10.1016/j.annonc.2020.07.004
   PubMed Web of Science ®Google Scholar
• Stege HM, Haist M, Schultheis S, et al. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. Cancer Immunol Immunother. 2021 Nov;70(11):3313–3322. doi: 10.1007/s00262-021-02925-4
   PubMed Web of Science ®Google Scholar
• Saiag P, Blom A. Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma. Lancet. 2022 Sep 24;400(10357):976–977. doi: 10.1016/S0140-6736(22)01749-4
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Sayehli C, Aulitzky WE, et al. Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies. Eur J Haematol. 2019 Feb;102(2):163–173. doi: 10.1111/ejh.13188
   PubMed Web of Science ®Google Scholar
• Becker JC, Hassel JC, Menzer C, et al. Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): a randomized, multicenter DeCOG/ADO study. J Clin Oncol. 2018;36(15_suppl):9527–9527. doi: 10.1200/JCO.2018.36.15_suppl.9527
   Web of Science ®Google Scholar
• Becker JC, Ugurel S, Leiter U, et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. Lancet. 2023 Jul 11;402(10404):798–808. doi: 10.1016/S0140-6736(23)00769-9
   PubMedGoogle Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018 May 10;378(19):1789–1801. doi: 10.1056/NEJMoa1802357
   PubMed Web of Science ®Google Scholar
• Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 Apr 30;399(10336):1718–1729. doi: 10.1016/S0140-6736(22)00562-1
   PubMed Web of Science ®Google Scholar
• Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020 Aug 1;38(22):2476–2487. doi: 10.1200/JCO.20.00201
   PubMed Web of Science ®Google Scholar
• Patel SP, Othus M, Chen Y, et al. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023 Mar 2;388(9):813–823. doi: 10.1056/NEJMoa2211437
   PubMed Web of Science ®Google Scholar
• Ricco G, Andrini E, Siepe G, et al. Multimodal strategy in localized Merkel cell carcinoma: where are we and where are we Heading? Int J Mol Sci. 2021 Sep 30;22(19):10629. doi: 10.3390/ijms221910629
   PubMed Web of Science ®Google Scholar
• Byar DP, Simon RM, Friedewald WT, et al. Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med. 1976 Jul 8;295(2):74–80. doi: 10.1056/NEJM197607082950204
   PubMed Web of Science ®Google Scholar